skip to main content

Defining outcomes for [beta]-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop.(Report)

Rickels, Michael R. ; Stock, Peter G. ; Koning, Eelco J. P. ; Piemonti, Lorenzo ; Pratschke, Johann ; Alejandro, Rodolfo ; Bellin, Melena D. ; Berney, Thierry ; Choudhary, Pratik ; Johnson, Paul R. ; Kandaswamy, Raja ; Kay, Thomas W. H. ; Keymeulen, Bart ; Kudva, Yogish C. ; Latres, Esther ; Langer, Robert M. ; Lehmann, Roger ; Ludwig, Barbara ; Markmann, James F. ; Marinac, Marjana ; Odorico, Jon S. ; Pattou, Francois ; Senior, Peter A. ; Shaw, James A. M. ; Vantyghem, Marie-Christine ; White, Steven

Transplant International, 2018, Vol.31(4), p.343(10) [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Defining outcomes for [beta]-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop.(Report)
  • Autor: Rickels, Michael R. ; Stock, Peter G. ; Koning, Eelco J. P. ; Piemonti, Lorenzo ; Pratschke, Johann ; Alejandro, Rodolfo ; Bellin, Melena D. ; Berney, Thierry ; Choudhary, Pratik ; Johnson, Paul R. ; Kandaswamy, Raja ; Kay, Thomas W. H. ; Keymeulen, Bart ; Kudva, Yogish C. ; Latres, Esther ; Langer, Robert M. ; Lehmann, Roger ; Ludwig, Barbara ; Markmann, James F. ; Marinac, Marjana ; Odorico, Jon S. ; Pattou, Francois ; Senior, Peter A. ; Shaw, James A. M. ; Vantyghem, Marie-Christine ; White, Steven
  • Assuntos: Peptides – Conferences, Meetings and Seminars ; Pancreatic Beta Cells – Conferences, Meetings and Seminars ; Diabetes Therapy – Conferences, Meetings and Seminars ; Hemoglobins – Conferences, Meetings and Seminars
  • É parte de: Transplant International, 2018, Vol.31(4), p.343(10)
  • Descrição: Byline: Michael R. Rickels, Peter G. Stock, Eelco J. P. Koning,Lorenzo Piemonti, Johann Pratschke, Rodolfo Alejandro, Melena D. Bellin,Thierry Berney, Pratik Choudhary, Paul R. Johnson, Raja Kandaswamy, Thomas W. H. Kay, Bart Keymeulen, Yogish C. Kudva, Esther Latres, Robert M. Langer, Roger Lehmann, Barbara Ludwig, James F. Markmann, Marjana Marinac, Jon S. Odorico, Francois Pattou, Peter A. Senior, James A. M. Shaw, Marie-Christine Vantyghem, Steven White Keywords: Outcome; islet clinical; pancreas clinical Summary [beta]-cell replacement therapy, available currently as pancreas or islet transplantation, has developed without a clear definition of graft functional and clinical outcomes. The International Pancreas & Islet Transplant Association (IPITA) and European Pancreas & Islet Transplantation Association (EPITA) held a workshop to develop consensus for an IPITA/EPITA Statement on the definition of function and failure of current and future forms of [beta]-cell replacement therapy. There was consensus that [beta]-cell replacement therapy could be considered as a treatment for [beta]-cell failure, regardless of etiology and without requiring undetectable C-peptide, accompanied by glycemic instability with either problematic hypoglycemia or hyperglycemia. Glycemic control should be assessed at a minimum by glycated hemoglobin (HbA.sub.1c) and the occurrence of severe hypoglycemia. Optimal [beta]-cell graft function is defined by near-normal glycemic control [HbA.sub.1c [less than or equal to] 6.5% (48 mmol/mol)] without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C-peptide. Good [beta]-cell graft function requires HbA.sub.1c 50%) reduction in insulin requirements and restoration of clinically significant C-peptide production. Marginal [beta]-cell graft function is defined by failure to achieve HbA.sub.1c < 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C-peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed [beta]-cell graft is defined by the absence of any evidence for clinically significant C-peptide production. Optimal and good functional outcomes are considered successful clinical outcomes. Article Note: M.R.R. and P.G.S. cochaired the organizing committee, presented at, chaired, and moderated sessions; E.J.P.de K., L.P., and J.P. served on the organizing committee, presented at, chaired, and/or moderated sessions; R.A., M.D.B., T.B., P.C., P.R.J., R.K. T.W.H.K., B.K., Y.C.K., E.L., R.M.L., R.L., B.L., J.F.M., M.M., J.S.O., F.P., P.A.S., J.A.M.S., M.-C.V., and S.W. presented at, chaired, and/or moderated sessions. All authors and the additional workshop participants listed in the Appendix approved the manuscript.
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.